Publications by authors named "Jeffrey C Allen"

50Publications

Diffuse midline glioma with novel, potentially targetable, fusion.

Cold Spring Harb Mol Case Stud 2020 10 7;6(5). Epub 2020 Oct 7.

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York 10032, USA.

View Article and Find Full Text PDF
October 2020

Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.

J Neurooncol 2018 Sep 8;139(3):749-755. Epub 2018 Jun 8.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
September 2018

Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors.

J Neurooncol 2016 09 12;129(3):541-544. Epub 2016 Jul 12.

Division of Pediatric Hematology/Oncology, Department of Pediatrics and Otolaryngology, NYU Langone Medical Center and Perlmutter Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
September 2016

Management of CNS germinoma.

CNS Oncol 2015 29;4(4):273-9. Epub 2015 Jun 29.

Langone Medical Center, New York University, New York, NY, USA.

View Article and Find Full Text PDF
April 2016

Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.

J Clin Oncol 2015 Aug 22;33(22):2464-71. Epub 2015 Jun 22.

Stewart Goldman, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Eric Bouffet, The Hospital for Sick Children, Toronto, ON, Canada; Paul G. Fisher, Lucile Packard Children's Hospital Stanford, Palo Alto; Cynthia S. Kretschmar, Children's Hospital Los Angeles, Los Angeles; Tianni Zhou, California State University, Long Beach; Allen B. Buxton, Children's Oncology Group, Monrovia, CA; Jeffrey C. Allen and Bernadine Donahue, New York University Langone Medical Center, New York, NY; Patricia L. Robertson, University of Michigan C.S. Mott Children's Hospital, Ann Arbor; Paul J. Chuba, St. John Hospital and Medical Center, Grosse Pointe, MI; and Ian F. Pollack, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA.

View Article and Find Full Text PDF
August 2015

The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Cancer Res 2015 Jan 7;75(1):16-21. Epub 2014 Nov 7.

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri. Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, Missouri.

View Article and Find Full Text PDF
January 2015

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

Neuro Oncol 2014 Oct 6;16(10):1408-16. Epub 2014 May 6.

NYU Comprehensive Neurofibromatosis Center, Division of Pediatric Hematology/Oncology, Department of Pediatrics and Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York (M.A.K., G.L., A.M., J.C.A.); Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania (M.J.F., A.J.S.); Department of Radiology, NYU Langone Medical Center, New York, New York (S.S.M., M.C.B.); The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (K.J.C.); Division of Pediatric Neurosurgery, Department of Neurosurgery, NYU Langone Medical Center, New York, New York (J.H.W., D.H.H.); Division of Biostatistics, Department of Population Health and The Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York (J.D.G., T.H.); Department of Neurosurgery, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania (A.C.R); Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California (G.D.); German Cancer Research Center and University Hospital, Heidelberg, Germany (D.T.W.J., A.K., S.M.P.); Division of Neuropathology, Department of Pathology, Johns Hopkins University, Baltimore, Maryland (C.G.E.); Division of Neuropathology, Department of Pathology, Department of Neurosurgery and Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York (D.Z.).

View Article and Find Full Text PDF
October 2014

Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study.

J Neurooncol 2014 May 4;118(1):93-100. Epub 2014 Apr 4.

12-718 C.S. Mott Children's Hospital, University of Michigan, 1540 E. Hospital Drive, Ann Arbor, MI, 48109, USA,

View Article and Find Full Text PDF
May 2014

Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

Neuro Oncol 2014 Jan 4;16(2):292-7. Epub 2013 Dec 4.

Corresponding author: Matthias A. Karajannis, MD, MS, NYU Langone Medical Center, Hassenfeld Children's Center for Cancer and Blood Disorders, 160 East 32nd Street, 2nd floor, New York, NY 10016.

View Article and Find Full Text PDF
January 2014

Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Neurology 2013 Nov;81(21 Suppl 1):S15-24

From the Division of Oncology (M.J.F.), Neuroradiology Section, Department of Radiology (L.T.B.), and Neuro-Ophthalmology Service (G.T.L.), The Children's Hospital of Philadelphia; Department of Pediatrics (M.J.F.) and Departments of Neurology and Ophthalmology (G.T.L.), The Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Departments of Neurology, Ophthalmology, and Pediatrics (R.A.A.), Gilbert Family Neurofibromatosis Institute, Children's National Medical Center, Washington, DC; Departments of Pediatrics and Neurology (J.C.A.), NYU Cancer Institute, NYU Langone Medical Center, New York, NY; Children's Hospital at Westmead Clinical School (S.L.A.-H.), The University of Sydney, Australia; Department of Neurology (S.L.A.-H.), The Children's Hospital at Westmead, Sydney, Australia; University of Pennsylvania School of Medicine (L.T.B.), Philadelphia; Department of Neurology (R.E.F.), Guy's and St. Thomas' NHS Foundation Trust and Institute of Psychiatry, King's College London; Department of Neurology (D.H.G.), Washington University School of Medicine, St. Louis, MO; Department of Pediatrics (R.L.), Feinberg School of Medicine, Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago (R.L.); Pediatric Oncology Branch (S.M.), National Cancer Institute, National Institutes of Health, Bethesda, MD; and Department of Neurology (N.J.U.), Boston Children's Hospital, Harvard Medical School, Boston, MA.

View Article and Find Full Text PDF
November 2013